Tagged cannabis

DEA Marijuana Policy  Reform - Matthew Strait you're Fired - Highlighted in Heated Oversight Congressional Hearing
Press Release

DEA Marijuana Policy Reform - Matthew Strait you're Fired - Highlighted in Heated Oversight Congressional Hearing

"This is insanity," declares Duane Boise, CEO of MMJ International Holdings, echoing the sentiments of lawmakers and researchers alike. The 2020 House Oversight Committee hearing, and ongoing developments, have laid bare the Drug Enforcement Administration's (DEA) persistent obstruction of legitimate cannabis research, a battle MMJ has been fighting since their 2018 application. Despite bipartisan congressional outrage, as highlighted by Representative Earl "Buddy" Carter's scathing critique of the DEA's "epitome of ineptitude," and the agency's own hollow defenses, the DEA, represented by figures like Matthew Strait and Thomas Prevoznik, continues to delay and deny, hindering vital medical advancements. Boise's lawsuit against the DEA underscores the urgent need for reform, as the agency's actions not only impede scientific progress but also deny patients access to potentially life-changing treatments, a situation that demands immediate structural changes in federal cannabis policy.

Read More
Press Release

MMJ’s FDA-First Cannabis Pharmaceutical Model Thrives Amid DEA Regulatory Gridlock

The DEA is "out of touch" and resistant to reform, stated Ben Kovler. Yet, amid this uncertainty, MMJ International Holdings has charted a distinct course-one rooted in pharmaceutical rigor-that's positioning the company as a trailblazer in the medical cannabis space.

Read More
Press Release

DOJ Makes Major Announcement - a Major Boost for MMJ'S Cannabis Research and DEA Accountability

The Department of Justice (DOJ) has announced that it will no longer defend statutory protections that currently shield Administrative Law Judges (ALJs) from removal. This significant shift is expected to bolster MMJ International Holdings' ongoing lawsuit against the Drug Enforcement Administration (DEA), which has been criticized for stalling MMJ's application to cultivate pharmaceutical-grade marijuana for medical research.

Read More
Key FDA Marijuana Response, MMJ International Holdings Advances Cannabis-Derived Therapeutics for Huntington’s Disease
Press Release

Key FDA Marijuana Response, MMJ International Holdings Advances Cannabis-Derived Therapeutics for Huntington’s Disease

MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has obstructed domestic cannabis research despite the Right To Try and the Medical Marijuana Research Expansion Act. MMJ accuses the DEA of bias in restricting MMJ to cultivate its proprietary marijuana cultivars necessary for research and pharmaceutical drug manufacturing. A pending federal court ruling in Rhode Island will set a significant precedent, challenging DEA authority and potentially easing regulatory barriers for MMJ's future cannabinoid drug development.

MEET DEA DIVERSION Thomas Prevoznik - The man behind the DEA marijuana scam- He Defied Presidential Mandates on Cannabis Research and Right to Try 

Read More
Press Release

MMJ Shaking Up DEA Anti Marijuana Policy, Supreme Court Overturns Chevron Doctrine

Duane Boise, President of MMJ BioPharma Cultivation, stated, "I think most Americans want judges who don't mind telling the truth and don't mind saying we're wrong. Unlike the DEA's arrogant attitude of, if we make a mistake, we won't be called on it, however MMJ is doing exactly that. The most immature thing you can do is say, 'no, no, I didn't make a mistake.' The mature thing to do, that all adults learn to do in this country is to say, 'oops, that was a mistake. I'm going to fix it. I'm sorry.'"

Read More